Selected research
Industry Research
Brand Drugs Industry Research Report 2026
Market perspective
The global Brand Drugs market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
North America: the Brand Drugs market is projected to increase from US$ million in 2026 to US$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the Brand Drugs market is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the Brand Drugs market is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of Brand Drugs include Takeda, Takeda, Teva, Sanofi, Johnson & Johnson, Novartis, Novo Nordisk, Roche and Eli Lilly, among others; in 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
Read the full market overview
This report quantifies the global Brand Drugs market in terms of revenue (US$ million) and, where applicable, service volume (k units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/k units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Brand Drugs.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Brand Drugs Market by Company
Takeda
Takeda
Teva
Sanofi
Johnson & Johnson
Novartis
Novo Nordisk
Roche
Eli Lilly
Pfizer
GlaxoSmithKline (GSK)
Bayer
Amgen
AbbVie
AbbVie
AstraZeneca
Merck & Co. (MSD)
Gilead Sciences
Bristol-Myers Squibb
Boehringer Ingelheim
Brand Drugs Segment by Type
Biopharmaceutical
Chemistry Medicine
Brand Drugs Segment by Application
Hospital
Clinic
Other
Brand Drugs Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Colombia
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Brand Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Brand Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Brand Drugs.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Brand Drugs companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Biopharmaceutical
- Chemistry Medicine
Applications
- Hospital
- Clinic
- Other
Companies covered
- Takeda
- Takeda
- Teva
- Sanofi
- Johnson & Johnson
- Novartis
- Novo Nordisk
- Roche
- Eli Lilly
- Pfizer
- GlaxoSmithKline (GSK)
- Bayer
- Amgen
- AbbVie
- AbbVie
- AstraZeneca
- Merck & Co. (MSD)
- Gilead Sciences
- Bristol-Myers Squibb
- Boehringer Ingelheim
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Brand Drugs by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 Biopharmaceutical
- 2.2.3 Chemistry Medicine
- 2.3 Brand Drugs by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Hospital
- 2.3.3 Clinic
- 2.3.4 Other
- 2.4 Assumptions and Limitations
3 Brand Drugs Breakdown Data by Type
- 3.1 Global Brand Drugs Historic Market Size by Type (2021-2026)
- 3.2 Global Brand Drugs Forecasted Market Size by Type (2027-2032)
4 Brand Drugs Breakdown Data by Application
- 4.1 Global Brand Drugs Historic Market Size by Application (2021-2026)
- 4.2 Global Brand Drugs Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global Brand Drugs Market Perspective (2021-2032)
- 5.2 Global Brand Drugs Growth Trends by Region
- 5.2.1 Global Brand Drugs Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 Brand Drugs Historic Market Size by Region (2021-2026)
- 5.2.3 Brand Drugs Forecasted Market Size by Region (2027-2032)
- 5.3 Brand Drugs Market Dynamics
- 5.3.1 Brand Drugs Industry Trends
- 5.3.2 Brand Drugs Market Drivers
- 5.3.3 Brand Drugs Market Challenges
- 5.3.4 Brand Drugs Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top Brand Drugs Players by Revenue
- 6.1.1 Global Top Brand Drugs Players by Revenue (2021-2026)
- 6.1.2 Global Brand Drugs Revenue Market Share by Players (2021-2026)
- 6.2 Global Brand Drugs Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of Brand Drugs Head Office and Area Served
- 6.4 Global Brand Drugs Players, Product Type & Application
- 6.5 Global Brand Drugs Manufacturers Established Date
- 6.6 Global Brand Drugs Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America Brand Drugs Market Size (2021-2032)
- 7.2 North America Brand Drugs Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America Brand Drugs Market Size by Country (2021-2026)
- 7.4 North America Brand Drugs Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe Brand Drugs Market Size (2021-2032)
- 8.2 Europe Brand Drugs Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe Brand Drugs Market Size by Country (2021-2026)
- 8.4 Europe Brand Drugs Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific Brand Drugs Market Size (2021-2032)
- 9.2 Asia-Pacific Brand Drugs Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific Brand Drugs Market Size by Country (2021-2026)
- 9.4 Asia-Pacific Brand Drugs Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America Brand Drugs Market Size (2021-2032)
- 10.2 South America Brand Drugs Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America Brand Drugs Market Size by Country (2021-2026)
- 10.4 South America Brand Drugs Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa Brand Drugs Market Size (2021-2032)
- 11.2 Middle East & Africa Brand Drugs Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa Brand Drugs Market Size by Country (2021-2026)
- 11.4 Middle East & Africa Brand Drugs Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 Takeda
- 12.1.1 Takeda Company Information
- 12.1.2 Takeda Business Overview
- 12.1.3 Takeda Revenue in Brand Drugs Business (2021-2026)
- 12.1.4 Takeda Brand Drugs Product Portfolio
- 12.1.5 Takeda Recent Developments
- 12.2 Takeda
- 12.2.1 Takeda Company Information
- 12.2.2 Takeda Business Overview
- 12.2.3 Takeda Revenue in Brand Drugs Business (2021-2026)
- 12.2.4 Takeda Brand Drugs Product Portfolio
- 12.2.5 Takeda Recent Developments
- 12.3 Teva
- 12.3.1 Teva Company Information
- 12.3.2 Teva Business Overview
- 12.3.3 Teva Revenue in Brand Drugs Business (2021-2026)
- 12.3.4 Teva Brand Drugs Product Portfolio
- 12.3.5 Teva Recent Developments
- 12.4 Sanofi
- 12.4.1 Sanofi Company Information
- 12.4.2 Sanofi Business Overview
- 12.4.3 Sanofi Revenue in Brand Drugs Business (2021-2026)
- 12.4.4 Sanofi Brand Drugs Product Portfolio
- 12.4.5 Sanofi Recent Developments
- 12.5 Johnson & Johnson
- 12.5.1 Johnson & Johnson Company Information
- 12.5.2 Johnson & Johnson Business Overview
- 12.5.3 Johnson & Johnson Revenue in Brand Drugs Business (2021-2026)
- 12.5.4 Johnson & Johnson Brand Drugs Product Portfolio
- 12.5.5 Johnson & Johnson Recent Developments
- 12.6 Novartis
- 12.6.1 Novartis Company Information
- 12.6.2 Novartis Business Overview
- 12.6.3 Novartis Revenue in Brand Drugs Business (2021-2026)
- 12.6.4 Novartis Brand Drugs Product Portfolio
- 12.6.5 Novartis Recent Developments
- 12.7 Novo Nordisk
- 12.7.1 Novo Nordisk Company Information
- 12.7.2 Novo Nordisk Business Overview
- 12.7.3 Novo Nordisk Revenue in Brand Drugs Business (2021-2026)
- 12.7.4 Novo Nordisk Brand Drugs Product Portfolio
- 12.7.5 Novo Nordisk Recent Developments
- 12.8 Roche
- 12.8.1 Roche Company Information
- 12.8.2 Roche Business Overview
- 12.8.3 Roche Revenue in Brand Drugs Business (2021-2026)
- 12.8.4 Roche Brand Drugs Product Portfolio
- 12.8.5 Roche Recent Developments
- 12.9 Eli Lilly
- 12.9.1 Eli Lilly Company Information
- 12.9.2 Eli Lilly Business Overview
- 12.9.3 Eli Lilly Revenue in Brand Drugs Business (2021-2026)
- 12.9.4 Eli Lilly Brand Drugs Product Portfolio
- 12.9.5 Eli Lilly Recent Developments
- 12.10 Pfizer
- 12.10.1 Pfizer Company Information
- 12.10.2 Pfizer Business Overview
- 12.10.3 Pfizer Revenue in Brand Drugs Business (2021-2026)
- 12.10.4 Pfizer Brand Drugs Product Portfolio
- 12.10.5 Pfizer Recent Developments
- 12.11 GlaxoSmithKline (GSK)
- 12.11.1 GlaxoSmithKline (GSK) Company Information
- 12.11.2 GlaxoSmithKline (GSK) Business Overview
- 12.11.3 GlaxoSmithKline (GSK) Revenue in Brand Drugs Business (2021-2026)
- 12.11.4 GlaxoSmithKline (GSK) Brand Drugs Product Portfolio
- 12.11.5 GlaxoSmithKline (GSK) Recent Developments
- 12.12 Bayer
- 12.12.1 Bayer Company Information
- 12.12.2 Bayer Business Overview
- 12.12.3 Bayer Revenue in Brand Drugs Business (2021-2026)
- 12.12.4 Bayer Brand Drugs Product Portfolio
- 12.12.5 Bayer Recent Developments
- 12.13 Amgen
- 12.13.1 Amgen Company Information
- 12.13.2 Amgen Business Overview
- 12.13.3 Amgen Revenue in Brand Drugs Business (2021-2026)
- 12.13.4 Amgen Brand Drugs Product Portfolio
- 12.13.5 Amgen Recent Developments
- 12.14 AbbVie
- 12.14.1 AbbVie Company Information
- 12.14.2 AbbVie Business Overview
- 12.14.3 AbbVie Revenue in Brand Drugs Business (2021-2026)
- 12.14.4 AbbVie Brand Drugs Product Portfolio
- 12.14.5 AbbVie Recent Developments
- 12.15 AbbVie
- 12.15.1 AbbVie Company Information
- 12.15.2 AbbVie Business Overview
- 12.15.3 AbbVie Revenue in Brand Drugs Business (2021-2026)
- 12.15.4 AbbVie Brand Drugs Product Portfolio
- 12.15.5 AbbVie Recent Developments
- 12.16 AstraZeneca
- 12.16.1 AstraZeneca Company Information
- 12.16.2 AstraZeneca Business Overview
- 12.16.3 AstraZeneca Revenue in Brand Drugs Business (2021-2026)
- 12.16.4 AstraZeneca Brand Drugs Product Portfolio
- 12.16.5 AstraZeneca Recent Developments
- 12.17 Merck & Co. (MSD)
- 12.17.1 Merck & Co. (MSD) Company Information
- 12.17.2 Merck & Co. (MSD) Business Overview
- 12.17.3 Merck & Co. (MSD) Revenue in Brand Drugs Business (2021-2026)
- 12.17.4 Merck & Co. (MSD) Brand Drugs Product Portfolio
- 12.17.5 Merck & Co. (MSD) Recent Developments
- 12.18 Gilead Sciences
- 12.18.1 Gilead Sciences Company Information
- 12.18.2 Gilead Sciences Business Overview
- 12.18.3 Gilead Sciences Revenue in Brand Drugs Business (2021-2026)
- 12.18.4 Gilead Sciences Brand Drugs Product Portfolio
- 12.18.5 Gilead Sciences Recent Developments
- 12.19 Bristol-Myers Squibb
- 12.19.1 Bristol-Myers Squibb Company Information
- 12.19.2 Bristol-Myers Squibb Business Overview
- 12.19.3 Bristol-Myers Squibb Revenue in Brand Drugs Business (2021-2026)
- 12.19.4 Bristol-Myers Squibb Brand Drugs Product Portfolio
- 12.19.5 Bristol-Myers Squibb Recent Developments
- 12.20 Boehringer Ingelheim
- 12.20.1 Boehringer Ingelheim Company Information
- 12.20.2 Boehringer Ingelheim Business Overview
- 12.20.3 Boehringer Ingelheim Revenue in Brand Drugs Business (2021-2026)
- 12.20.4 Boehringer Ingelheim Brand Drugs Product Portfolio
- 12.20.5 Boehringer Ingelheim Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst